| Bioactivity | Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody[1]. |
| Name | Quavonlimab |
| CAS | 2254059-25-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Perets R, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021;32(3):395-403. |